Allergan, Duke Block Lash-Growth Generics

Law360, New York (April 23, 2013, 2:35 PM EDT) -- A North Carolina federal judge on Tuesday granted a permanent injunction to Allergan Inc. and Duke University against several planned generic versions of eyelash growth stimulant Latisse after previously finding the proposed drugs infringed on two patents, disregarding the protests of the generic-drug makers.

According to U.S. District Judge Catherine C. Eagles, Allergan and Duke would suffer permanent harm without an injunction against Apotex Inc., Sandoz Inc., Hi-Tech Pharmacal Co. Inc. and Actavis Inc. — formerly Watson Pharmaceuticals Inc. — making or selling generic versions of...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

ALLERGAN, INC. et al v. APOTEX INC., et al


Case Number

1:10-cv-00681

Court

North Carolina Middle

Nature of Suit

Patent

Judge

CATHERINE C. EAGLES

Date Filed

September 8, 2010


Case Title

ALLERGAN, INC., et al v. SANDOZ, INC.


Case Number

1:11-cv-00298

Court

North Carolina Middle

Nature of Suit

Patent

Judge

CATHERINE C. EAGLES

Date Filed

April 15, 2011


Case Title

ALLERGAN, INC. et al v. HI-TECH PHARMACAL CO., INC.


Case Number

1:11-cv-00650

Court

North Carolina Middle

Nature of Suit

Patent

Judge

CATHERINE C. EAGLES

Date Filed

August 17, 2011


Case Title

ALLERGAN, INC., et al v. WATSON PHARMACEUTICALS, INC., et al


Case Number

1:12-cv-00321

Court

North Carolina Middle

Nature of Suit

Patent

Judge

CATHERINE C. EAGLES

Date Filed

March 30, 2012

Law Firms

Companies

Government Agencies

Patents